Lingyun Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lingyun Cheng has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
William R. Freeman
Department of Ophthalmology Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
16 shared publications- Karl Y. Hostetler
Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA
7 shared publications Michael J. Sailor
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States
7 shared publicationsJames R. Beadle
6 shared publications- Jay Chhablani
UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania
6 shared publications Alejandra Nieto
Department of Ophthalmology, Jacobs Retina Center, University of California, San Diego, California, United States Department of Chemistry and Biochemistry, University of California, San Diego, California, United States
5 shared publications
Latest Publications
- Open Access
- 1 April 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (4) , 2755-63
A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics
Purpose:Proliferative vitreoretinopathy (PVR) is the most common cause of poor visual outcomes in association with retinal detachment surgeries and ocular trauma. Daunorubicin (DNR) has shown the strongest efficacy in proliferation inhibition in vitro. However, clinical studies showed only mild effect due to limitations of narrow therapeutic window and short vitreous half-life. Methods:Three milligrams of DNR-loaded particles were intravitreally injected into 18 pigmented rabbits and vitreous samples were collected up to 84 days for analysis. Thirty-seven rabbits were used for a dose-escalation (1, 3, 6 mg) safety and efficacy study in rabbit PVR model using a pre-treatment design. Results:Loading efficiency of DNR was 108.55±12μg per 1mg of the particles. Eighty four days of follow-up did not reveal any adverse reaction. Pharmacokinetic analysis demonstrated a vitreous half-life of 29 days with a maximum DNR concentration of 178 ng/ml and a minimum concentration of 29 ng/ml at day 84. DNR-loaded pSi particles were dosed 8 to 9 weeks before PVR induction and PVR severity score was dose dependent (Spearman ρ=-0.25, p=0.0005). PVR with tractional retinal detachment counted for 88% in the control group, 63% in the low dose group, 14% in the medium dose group, and 0% in the high dose group (Cochran-Armitage Trend Test, Z=8.99, ρ=-0.67, p<0.0001). Conclusions:DNR-loaded pSi particles can safely reside in the vitreous for at least 3 months. pSi based delivery rendered therapeutic window of DNR expanded by a factor of 862 and driven down the minimum effective concentration by a factor of 175.
- 1 April 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (4) , 2755-63
Open AccessA Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics
Purpose:Proliferative vitreoretinopathy (PVR) is the most common cause of poor visual outcomes in association with retinal detachment surgeries and ocular trauma. Daunorubicin (DNR) has shown the strongest efficacy in proliferation inhibition in vitro. However, clinical studies showed only mild effect due to limitations of narrow therapeutic window and short vitreous half-life. Methods:Three milligrams of DNR-loaded particles were intravitreally injected into 18 pigmented rabbits and vitreous samples were collected up to 84 days for analysis. Thirty-seven rabbits were used for a dose-escalation (1, 3, 6 mg) safety and efficacy study in rabbit PVR model using a pre-treatment design. Results:Loading efficiency of DNR was 108.55±12μg per 1mg of the particles. Eighty four days of follow-up did not reveal any adverse reaction. Pharmacokinetic analysis demonstrated a vitreous half-life of 29 days with a maximum DNR concentration of 178 ng/ml and a minimum concentration of 29 ng/ml at day 84. DNR-loaded pSi particles were dosed 8 to 9 weeks before PVR induction and PVR severity score was dose dependent (Spearman ρ=-0.25, p=0.0005). PVR with tractional retinal detachment counted for 88% in the control group, 63% in the low dose group, 14% in the medium dose group, and 0% in the high dose group (Cochran-Armitage Trend Test, Z=8.99, ρ=-0.67, p<0.0001). Conclusions:DNR-loaded pSi particles can safely reside in the vitreous for at least 3 months. pSi based delivery rendered therapeutic window of DNR expanded by a factor of 862 and driven down the minimum effective concentration by a factor of 175.
- 1 April 2015
- Published by Elsevier in Journal of Controlled Release
- Vol. 203, 109-117
Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model
- 1 April 2015
- Published by Elsevier in Journal of Controlled Release
- Vol. 203, 109-117
Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model
- 23 February 2015
- Published by Wiley in Acta Ophthalmologica
- Vol. 94 (4) , 391-396
Perioperative pharmacological management of choroidal detachment associated with rhegmatogenous retinal detachment
Purpose: To compare subtenon triamcinolone versus systemic dexamethasone for perisurgical management of primary rhegmatogenous retinal detachment presenting with a choroidal detachment (RRD/CD).Methods: Thirty consecutive primary RRD/CD patients were prospectively studied. Sixteen RRD/CD patients were injected with a 40 mg subtenon triamcinolone acetonide (TA) 5 days before a scheduled vitrectomy (TA group) while the other 14 RRD/CD patients were intravenously infused daily with 10 mg dexamethasone (Dex) for 5 days before a scheduled vitrectomy (Dex group). All patients were followed up for 6 months. Changes of choroid detachment on B ultrasonography and preoperative intraocular pressure (IOP), systemic and ocular steroid level, blood sugar, and postoperative macular oedema were compared between the two groups.Results: During 5 days of presurgical treatment, the IOP recovery from the baseline was 3.29 ± 4.56 mmHg for the TA group versus 1.16 ± 1.60 mmHg for the Dex group (p = 0.021). The height of CD decreased significantly more for the TA group (3.55 ± 1.33 versus 1.84 ± 1.5 mm, p = 0.0029). The physiological cortisol level in the plasma was significantly suppressed for the Dex group (8.35 ± 10.35 versus 51.9 ± 35.9 ng/ml, p = 0.01). Postoperative 1‐month macula was less oedematous for TA group (401 ± 196 versus 256 ± 66 μm, p = 0.0498).Conclusion: Subtenon TA seems to be a better option for perisurgical management of RRD/CD patients than systemic steroid application. Subtenon TA is more convenient for patients and imposes much less stress to patients’ hormones homeostasis. This is especially important for those who are suffering metabolic disorders and need vitrectomy surgery for repairing RRD/CD.
- 23 February 2015
- Published by Wiley in Acta Ophthalmologica
- Vol. 94 (4) , 391-396
Perioperative pharmacological management of choroidal detachment associated with rhegmatogenous retinal detachment
Purpose: To compare subtenon triamcinolone versus systemic dexamethasone for perisurgical management of primary rhegmatogenous retinal detachment presenting with a choroidal detachment (RRD/CD).Methods: Thirty consecutive primary RRD/CD patients were prospectively studied. Sixteen RRD/CD patients were injected with a 40 mg subtenon triamcinolone acetonide (TA) 5 days before a scheduled vitrectomy (TA group) while the other 14 RRD/CD patients were intravenously infused daily with 10 mg dexamethasone (Dex) for 5 days before a scheduled vitrectomy (Dex group). All patients were followed up for 6 months. Changes of choroid detachment on B ultrasonography and preoperative intraocular pressure (IOP), systemic and ocular steroid level, blood sugar, and postoperative macular oedema were compared between the two groups.Results: During 5 days of presurgical treatment, the IOP recovery from the baseline was 3.29 ± 4.56 mmHg for the TA group versus 1.16 ± 1.60 mmHg for the Dex group (p = 0.021). The height of CD decreased significantly more for the TA group (3.55 ± 1.33 versus 1.84 ± 1.5 mm, p = 0.0029). The physiological cortisol level in the plasma was significantly suppressed for the Dex group (8.35 ± 10.35 versus 51.9 ± 35.9 ng/ml, p = 0.01). Postoperative 1‐month macula was less oedematous for TA group (401 ± 196 versus 256 ± 66 μm, p = 0.0498).Conclusion: Subtenon TA seems to be a better option for perisurgical management of RRD/CD patients than systemic steroid application. Subtenon TA is more convenient for patients and imposes much less stress to patients’ hormones homeostasis. This is especially important for those who are suffering metabolic disorders and need vitrectomy surgery for repairing RRD/CD.
- Open Access
- 22 January 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (2) , 1070-1080
Surface Engineering of Porous Silicon Microparticles for Intravitreal Sustained Delivery of Rapamycin
Purpose.: To understand the relationship between rapamycin loading/release and surface chemistries of porous silicon (pSi) to optimize pSi-based intravitreal delivery system. Methods.: Three types of surface chemical modifications were studied: (1) pSi-COOH, containing 10-carbon aliphatic chains with terminal carboxyl groups grafted via hydrosilylation of undecylenic acid; (2) pSi-C12, containing 12-carbon aliphatic chains grafted via hydrosilylation of 1-dodecene; and (3) pSiO2-C8, prepared by mild oxidation of the pSi particles followed by grafting of 8-hydrocarbon chains to the resulting porous silica surface via a silanization. Results.: The efficiency of rapamycin loading follows the order (micrograms of drug/milligrams of carrier): pSiO2-C8 (105 ± 18) > pSi-COOH (68 ± 8) > pSi-C12 (36 ± 6). Powder X-ray diffraction data showed that loaded rapamycin was amorphous and dynamic drug-release study showed that the availability of the free drug was increased by 6-fold (compared with crystalline rapamycin) by using pSiO2-C8 formulation (P = 0.0039). Of the three formulations in this study, pSiO2-C8-RAP showed optimal performance in terms of simultaneous release of the active drug and carrier degradation, and drug-loading capacity. Released rapamycin was confirmed with the fingerprints of the mass spectrometry and biologically functional as the control of commercial crystalline rapamycin. Single intravitreal injections of 2.9 ± 0.37 mg pSiO2-C8-RAP into rabbit eyes resulted in more than 8 weeks of residence in the vitreous while maintaining clear optical media and normal histology of the retina in comparison to the controls. Conclusions.: Porous silicon–based rapamycin delivery system using the pSiO2-C8 formulation demonstrated good ocular compatibility and may provide sustained drug release for retina.
- 22 January 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (2) , 1070-1080
Open AccessSurface Engineering of Porous Silicon Microparticles for Intravitreal Sustained Delivery of Rapamycin
Purpose.: To understand the relationship between rapamycin loading/release and surface chemistries of porous silicon (pSi) to optimize pSi-based intravitreal delivery system. Methods.: Three types of surface chemical modifications were studied: (1) pSi-COOH, containing 10-carbon aliphatic chains with terminal carboxyl groups grafted via hydrosilylation of undecylenic acid; (2) pSi-C12, containing 12-carbon aliphatic chains grafted via hydrosilylation of 1-dodecene; and (3) pSiO2-C8, prepared by mild oxidation of the pSi particles followed by grafting of 8-hydrocarbon chains to the resulting porous silica surface via a silanization. Results.: The efficiency of rapamycin loading follows the order (micrograms of drug/milligrams of carrier): pSiO2-C8 (105 ± 18) > pSi-COOH (68 ± 8) > pSi-C12 (36 ± 6). Powder X-ray diffraction data showed that loaded rapamycin was amorphous and dynamic drug-release study showed that the availability of the free drug was increased by 6-fold (compared with crystalline rapamycin) by using pSiO2-C8 formulation (P = 0.0039). Of the three formulations in this study, pSiO2-C8-RAP showed optimal performance in terms of simultaneous release of the active drug and carrier degradation, and drug-loading capacity. Released rapamycin was confirmed with the fingerprints of the mass spectrometry and biologically functional as the control of commercial crystalline rapamycin. Single intravitreal injections of 2.9 ± 0.37 mg pSiO2-C8-RAP into rabbit eyes resulted in more than 8 weeks of residence in the vitreous while maintaining clear optical media and normal histology of the retina in comparison to the controls. Conclusions.: Porous silicon–based rapamycin delivery system using the pSiO2-C8 formulation demonstrated good ocular compatibility and may provide sustained drug release for retina.
- 1 August 2014
- Published by Elsevier in Acta Biomaterialia
- Vol. 10 (8) , 3505-3512
Porous silicon oxide–PLGA composite microspheres for sustained ocular delivery of daunorubicin
- 1 August 2014
- Published by Elsevier in Acta Biomaterialia
- Vol. 10 (8) , 3505-3512
Porous silicon oxide–PLGA composite microspheres for sustained ocular delivery of daunorubicin
- 1 April 2014
- Published by Wiley in Optometry and Vision Science
- Vol. 91 (4) , 412-418
Posterior Scleral Reinforcement on Progressive High Myopic Young Patients
Purpose: To evaluate the effect of posterior scleral reinforcement in controlling high myopic axial progression in young patients. Methods: Only one eye of each patient had posterior scleral reinforcement surgery. Before surgery and at each postoperative follow‐up, the best corrected visual acuity, intraocular pressure, refractive errors, indirect ophthalmoscopy, B‐type ultrasonography, and IOLMASTER reflected light biometry were performed on both eyes. The changes of axial length and the changes of refractive errors from the baseline were compared between the surgery eyes and the contralateral eyes. Results: Thirty patients had a mean age of 7.5 years and a mean spherical equivalent of −9.72 diopters. The mean elongation of axial length was significantly less in the surgery eye group than that in the contralateral eye group (0.75 mm vs. 0.94 mm, p < 0.0001, paired t test) after a mean follow‐up of 895 days. The surgical effect was mild but maintained during the follow‐up. The eyes with staphyloma gained less surgical effect when compared with the eyes without staphyloma (p = 0.0036). There was also a notable nonstatistically significant trend for younger patients to gain a larger surgical effect (p = 0.0986). Conclusions: Posterior scleral reinforcement surgery was found effective in slowing down high myopic axial progression in young patients within the study period, but the size of the effect was small. The surgical procedure is well tolerated without vision‐threatening complications.
- 1 April 2014
- Published by Wiley in Optometry and Vision Science
- Vol. 91 (4) , 412-418
Posterior Scleral Reinforcement on Progressive High Myopic Young Patients
Purpose: To evaluate the effect of posterior scleral reinforcement in controlling high myopic axial progression in young patients. Methods: Only one eye of each patient had posterior scleral reinforcement surgery. Before surgery and at each postoperative follow‐up, the best corrected visual acuity, intraocular pressure, refractive errors, indirect ophthalmoscopy, B‐type ultrasonography, and IOLMASTER reflected light biometry were performed on both eyes. The changes of axial length and the changes of refractive errors from the baseline were compared between the surgery eyes and the contralateral eyes. Results: Thirty patients had a mean age of 7.5 years and a mean spherical equivalent of −9.72 diopters. The mean elongation of axial length was significantly less in the surgery eye group than that in the contralateral eye group (0.75 mm vs. 0.94 mm, p < 0.0001, paired t test) after a mean follow‐up of 895 days. The surgical effect was mild but maintained during the follow‐up. The eyes with staphyloma gained less surgical effect when compared with the eyes without staphyloma (p = 0.0036). There was also a notable nonstatistically significant trend for younger patients to gain a larger surgical effect (p = 0.0986). Conclusions: Posterior scleral reinforcement surgery was found effective in slowing down high myopic axial progression in young patients within the study period, but the size of the effect was small. The surgical procedure is well tolerated without vision‐threatening complications.
- 1 March 2014
- Published by Elsevier in Journal of Controlled Release
- Vol. 178, 46-54
Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon
- 1 March 2014
- Published by Elsevier in Journal of Controlled Release
- Vol. 178, 46-54
Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon
- 1 November 2013
- Published by Elsevier in Experimental Eye Research
- Vol. 116, 161-168
Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles
- 1 November 2013
- Published by Elsevier in Experimental Eye Research
- Vol. 116, 161-168
Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles
- 18 October 2013
- Vol. 6 (5) , 600-605
Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration
AIM: To characterize temporal pattern of resolution and recurrence of naive choroidal neovascularization (CNV) secondary to wet age -related macular degeneration (AMD) treated with intravitreal bevacizumab on as needed regimen, and to analyze baseline risk factors for CNV resolution or recurrence. METHODS: Ninety-one eyes of 80 patients with newly diagnosed wet AMD were retrospectively studied. All eyes were treated with a round of three monthly intravitreal bevacizumab injections, followed by one additional 'bonus' injection after resolution of CNV activity. During follow -up, eyes were monitored with fluorescein angiography, optical coherence tomography, and best -corrected visual acuity (BCVA). In case of recurrences of CNV activity, eyes were retreated with other rounds of bevacizumab injections following the same treatment protocol. RESULTS: Over a median follow -up of 532d, the median resolution time of CNV activity in the first, second, and third treatment round was 98d, 126d, and 111d, respectively. The median recurrence time for the three rounds was 154d, 126d, and 151d, respectively. No significant difference in resolution time (P=0.09) or in recurrence time (P=0.11) was detected among treatment rounds. Age (P=0.0082) and lens status (P=0.035) were found to be associated with CNV resolution; for every 1-year increase in age there was 4% greater chance of CNV resolution; Phakic eyes demonstrated a 33% better chance to experience CNV resolution than pseudophakic eyes. For CNV recurrence, lens status (P=0.0009) and gender (P=0.0446) were found to be predictive; pseudophakic eyes had a 3.69 -fold greater risk to experience recurrence of CNV activity compared to phakic eyes; males had a 2.19 -fold greater risk to experience recurrence of CNV activity than females. No significant BCVA changes among three treatment rounds were noted (P=0.56). CONCLUSION: Resolution time and recurrence time of CNV activity were not significantly different among treatment rounds, suggesting absence of tachyphylaxis to bevacizumab. A cautious decision should be made upon discontinuing treatment in wet AMD eyes of younger or pseudophakic patients, which showed slower response to bevacizumab. In addition, wet AMD eyes of male or pseudophakic patients should be evaluated more carefully after stopping the treatment, because they may have early reactivation of the CNV. BCVA was preserved by bevacizumab treatment despite multiple recurrences.
- 18 October 2013
- Vol. 6 (5) , 600-605
Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration
AIM: To characterize temporal pattern of resolution and recurrence of naive choroidal neovascularization (CNV) secondary to wet age -related macular degeneration (AMD) treated with intravitreal bevacizumab on as needed regimen, and to analyze baseline risk factors for CNV resolution or recurrence. METHODS: Ninety-one eyes of 80 patients with newly diagnosed wet AMD were retrospectively studied. All eyes were treated with a round of three monthly intravitreal bevacizumab injections, followed by one additional 'bonus' injection after resolution of CNV activity. During follow -up, eyes were monitored with fluorescein angiography, optical coherence tomography, and best -corrected visual acuity (BCVA). In case of recurrences of CNV activity, eyes were retreated with other rounds of bevacizumab injections following the same treatment protocol. RESULTS: Over a median follow -up of 532d, the median resolution time of CNV activity in the first, second, and third treatment round was 98d, 126d, and 111d, respectively. The median recurrence time for the three rounds was 154d, 126d, and 151d, respectively. No significant difference in resolution time (P=0.09) or in recurrence time (P=0.11) was detected among treatment rounds. Age (P=0.0082) and lens status (P=0.035) were found to be associated with CNV resolution; for every 1-year increase in age there was 4% greater chance of CNV resolution; Phakic eyes demonstrated a 33% better chance to experience CNV resolution than pseudophakic eyes. For CNV recurrence, lens status (P=0.0009) and gender (P=0.0446) were found to be predictive; pseudophakic eyes had a 3.69 -fold greater risk to experience recurrence of CNV activity compared to phakic eyes; males had a 2.19 -fold greater risk to experience recurrence of CNV activity than females. No significant BCVA changes among three treatment rounds were noted (P=0.56). CONCLUSION: Resolution time and recurrence time of CNV activity were not significantly different among treatment rounds, suggesting absence of tachyphylaxis to bevacizumab. A cautious decision should be made upon discontinuing treatment in wet AMD eyes of younger or pseudophakic patients, which showed slower response to bevacizumab. In addition, wet AMD eyes of male or pseudophakic patients should be evaluated more carefully after stopping the treatment, because they may have early reactivation of the CNV. BCVA was preserved by bevacizumab treatment despite multiple recurrences.
- 1 September 2013
- Vol. 49 (9) , 847-50
[Progress in sustained-release drug delivery system for treatment of posterior segment eye diseases].
There is an urgent requirement to find effective therapeutic procedures for the treatment of refractory eye diseases of posterior segment such as posterior uveitis, proliferative vitreoretinopathy, and macular edema associated with diabetes and retinal vein occlusion. Due to systemic side effect developed from systemic drug administration and the low efficiency of topical drug administration, implantable drug devices for the treatment of posterior segment diseases have been explored. In recent years, three different intraocular implantable devices (ganciclovir, fluocinolone acetonide and dexamethasone) have been approved by FDA and showed exciting clinical efficacy. However, these devices have surgical complications and the drug-related side effects. Recently, transscleral drug delivery to the posterior segment has been investigated. Transscleral drug delivery has advantages of large scleral surface area, better safety profile, easily drug administration and could evolve into an effective route with the use of novel biomaterials and the study of drug delivery methods.
- 1 September 2013
- Vol. 49 (9) , 847-50
[Progress in sustained-release drug delivery system for treatment of posterior segment eye diseases].
There is an urgent requirement to find effective therapeutic procedures for the treatment of refractory eye diseases of posterior segment such as posterior uveitis, proliferative vitreoretinopathy, and macular edema associated with diabetes and retinal vein occlusion. Due to systemic side effect developed from systemic drug administration and the low efficiency of topical drug administration, implantable drug devices for the treatment of posterior segment diseases have been explored. In recent years, three different intraocular implantable devices (ganciclovir, fluocinolone acetonide and dexamethasone) have been approved by FDA and showed exciting clinical efficacy. However, these devices have surgical complications and the drug-related side effects. Recently, transscleral drug delivery to the posterior segment has been investigated. Transscleral drug delivery has advantages of large scleral surface area, better safety profile, easily drug administration and could evolve into an effective route with the use of novel biomaterials and the study of drug delivery methods.